Key Points
- Director Steven Gannon sold 10,000 Xenon Pharmaceuticals shares at an average price of $64.06, generating $640,600. The transaction reduced his holdings by 84.25%, leaving him with 1,870 shares.
- Xenon’s stock opened at $64.23, with a $6.21 billion market capitalization, and has traded between $35.60 and $72.66 over the past year. The company posted quarterly EPS of negative $1.11, beating estimates by $0.05.
- Institutional investors own 95.45% of the stock, while analysts maintain a consensus “Buy” rating and an average price target of $77.13.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) Director Steven Gannon sold 10,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the sale, the director owned 1,870 shares in the company, valued at $119,792.20. The trade was a 84.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Xenon Pharmaceuticals Stock Down 1.6%
XENE opened at $64.23 on Friday. The company has a market cap of $6.21 billion, a P/E ratio of -13.55 and a beta of 0.62. The firm's 50-day moving average price is $61.13 and its 200-day moving average price is $54.94. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same quarter last year, the firm earned ($1.07) earnings per share. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.
Institutional Trading of Xenon Pharmaceuticals
A number of hedge funds have recently modified their holdings of XENE. BlackRock Inc. acquired a new stake in Xenon Pharmaceuticals during the second quarter worth about $454,057,000. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $56,637,000. Wellington Management Group LLP lifted its holdings in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock valued at $144,936,000 after acquiring an additional 1,435,096 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Xenon Pharmaceuticals by 1,968.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company's stock valued at $38,650,000 after acquiring an additional 820,608 shares during the period. Finally, Vestal Point Capital LP boosted its position in Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company reissued an "overweight" rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Royal Bank Of Canada dropped their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a research note on Friday, August 7th. Finally, Wall Street Zen raised Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $77.13.
Read Our Latest Stock Analysis on XENE
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
